Evidence map›Paper›PMID 38734900›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2024

Prophylactic vaccination inducing anti-Env antibodies can result in protection against HTLV-1 challenge in macaques.

Midori Nakamura-Hoshi, Hiroshi Ishii, Takushi Nomura, Masako Nishizawa, Trang Thi Thu Hau, Nozomi Kuse, Midori Okazaki, Akira Ainai, Tadaki Suzuki, Hideki Hasegawa and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. A promising advance in blocking HTLV-1 transmission: Addressing a global public health problem.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Midori Nakamura-HoshiAIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Hiroshi IshiiAIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Takushi NomuraAIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan.
Masako NishizawaAIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Trang Thi Thu HauAIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Nozomi KuseAIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Midori OkazakiAIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Akira AinaiDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Tadaki SuzukiDepartment of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Hideki HasegawaCenter for Influenza and Respiratory Virus Research, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Takeshi YoshidaAIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Management Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Kenzo YonemitsuManagement Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Yuriko SuzakiManagement Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Yasushi AmiManagement Department of Biosafety, Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
Hiroyuki YamamotoAIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan; Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.
Tetsuro MatanoAIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan; Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan; Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. Electronic address: tmatano@niid.go.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human T cell leukemia/T-lymphotropic virus type 1 (HTLV-1) infection occurs by cell-to-cell transmission and can induce fatal adult T cell leukemia. Vaccine development is critical for the control of HTLV-1 transmission. However, determining whether vaccine-induced anti-Env antibodies can prevent cell-to-cell HTLV-1 transmission is challenging. Here, we examined the protective efficacy of a vaccine inducing anti-Env antibodies against HTLV-1 challenge in cynomolgus macaques. Eight of 10 vaccinated macaques produced anti-HTLV-1 neutralizing antibodies (NAbs) and were protected from an intravenous challenge with 10

Indexed as

Antibodies, NeutralizingHTLV-I InfectionsHuman T-lymphotropic virus 1VaccinationAnimalsAntibodies, ViralCD8-Positive T-LymphocytesDisease Models, AnimalGene Products, envHumansMacaca fascicularisViral LoadViral VaccinesAntibodies, NeutralizingAntibodies, ViralGene Products, envViral Vaccinescell-to-cell transmissionHTLV-1macaque modelneutralizing antibodyvaccine

Identifiers

PMID38734900
PMCPMC11286815

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.